S&P Futures
5,485.75 -18.25 (-0.33%) Dow Futures
40,678.00 -120.00 (-0.29%) Nasdaq Futures
18,794.00 -70.00 (-0.37%) Russell 2000 Futures
2,087.30 -13.70 (-0.65%) Crude Oil
66.37 +0.62 (+0.94%) Gold
2,547.40 +4.30 (+0.17%)
BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
| Previous Close | 7.67 |
| Open | 7.67 |
| Bid | 6.71 x 100 |
| Ask | 8.94 x 100 |
| Day's Range | 7.55 - 7.91 |
| 52 Week Range | 4.03 - 8.88 |
| Volume | |
| Avg. Volume | 2,715,275 |
| Market Cap | 1.597B |
| Beta (5Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.45 |
GlobeNewswireBioCryst Presents New ORLADEYO? (berotralstat) Data at 7th Bradykinin Symposium
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes. The company is presenting the posters at the 7th Bradykinin Symposium in Berlin fr
- GlobeNewswire
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company’s new chief medical officer, effective immediately. Dr. Fong joins Dr. Helen Thackray, the company’s chief research and development officer, and Dr. Bill Sheridan, the company’s chief development officer, as physicians on the company’s leadership team. “We continue to advance our pipeline of novel therapies
- GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,025 shares, of BioCryst common stock. The options and RSUs were granted as of August 30, 2024, as inducements material to each employee entering into empl
